Uncategorized

$CUI To Participate, Midwest IDEAS Investor Conference, Aug 30, Chicago

TUALATIN, Ore., Aug. 17, 2017  – CUI Global, Inc. (NASDAQ: CUI) today announced its participation at the Midwest IDEAS Investor Conference on Wednesday, August 30, 2017 in Chicago, IL.

William Clough, chairman, president, and chief executive officer, is scheduled to present on that day at 11:20 am CT/12:20 pm ET. Mr. Clough will be joined by Daniel Ford, chief financial officer and chief operating officer of Energy Division, to host one-on-one meetings with institutional investors throughout the day.

Management’s presentation will be webcast live and available for replay on the Investor Relations section of the CUI Global, Inc. website, www.cuiglobal.com.

To attend or learn more about CUI Global’s participation at the Conference, please contact Sanjay M. Hurry at 212-838-3777 or shurry@lhai.com.

About CUI Global, Inc. 

Delivering Innovative Technologies for an Interconnected World . . .

CUI Global, Inc. is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. From Orbital Gas Systems’ advanced GasPT platform targeting the energy sector, to CUI Inc.’s digital power platform serving the networking and telecom space, CUI Global and its subsidiaries have built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. But most importantly, a commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit www.cuiglobal.com.

Important Cautions Regarding Forward Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The Company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the Company and its operations, are included in certain forms the Company has filed with the Securities and Exchange Commission.

Media Contact:CUI Global, Inc.
Jeff Schnabel

Main: 503-612-2300
press@cuiglobal.com

External Investor Relations contact:LHA
Sanjay M. Hurry
212-838-3777

cuiglobal@lhai.com

Thursday, August 17th, 2017 Uncategorized Comments Off

$MDVX Names Charlie Farrahar CFO

ATLANTA, GA–(Aug 17, 2017) – Medovex Corp. (NASDAQ: MDVX) (“Medovex” or the “Company”), the developer of the DenerveX™ System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to back pain, today reported it has named Charlie Farrahar as its Chief Financial Officer.

Charlie Farrahar is a Certified Public Accountant with over 30 years of managerial finance, administration, human resource and risk management experience in the public, private and non-profit sectors. Mr. Farrahar was the first Chief Financial officer of the Company from its inception through IPO. He remained with the Company as its Secretary only from January 2015 until August 2017, when he agreed to resume the CFO role.

Mr. Farrahar currently serves as Chief Financial Officer for several small private biotech companies in the research and development stage. In 2003 he joined a private governmental assistance startup as it’s CFO and Director of Human Resources, helping with the sale of that company to a private entity in 2011 after it had grown to a multi-state operation with over 400 employees. In the late 1990′s he was CFO of Credit Depot Corp. (Nasdaq).

At its August 16, 2017 quarterly Board meeting, the Board asked Charlie Farrahar, Company Secretary, to become Chief Financial Officer, a role he held from the inception of the Company through its initial public offering. Jeffery Wright, the former CFO, agreed to become the Company’s first Controller.

Jarrett Gorlin, Medovex Chief Executive Officer, stated, “We’re excited by the enthusiastic reception we’ve seen thus far to the Denervex product and realize that we have to properly support sustained revenue growth. One area affected by this growth is the financial/accounting function. With the addition of overseas sales and all the administration that entails, we were no longer able to have just one full-time person in the finance area.”

Gorlin continued, “We asked Charlie Farrahar to become CFO so Jeff Wright could focus on assisting our sales and distribution efforts as we expand sales into multiple countries. They have complementary skill sets and work well together. Their combined experience should allow us to properly steward anticipated growth associated with the launch of a successful new product targeting a broad audience.”

The Company’s DenerveX System recently received CE Mark approval and clearance for commercialization in the European countries and offers a unique way to perform a Facet Joint Syndrome treatment.

Facet Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal arthritis, or facet joint osteoarthritis, is a significant health and economic problem in the United States and other countries in the EU and Rest of World affecting millions each year. Current treatment options are generally temporary and there is no proven long-lasting option for FJS.

The DenerveX System is a highly differentiated technology. It denervates and removes capsular tissue from the Facet Joint in one single procedure. Treatment results from the combined effect of a deburring or polishing action and RF ablation treatment on the Facet Joint. Using this new technique, the slowly rotating burr removes the targeted facet joint synovial membrane and joint surface while the heat ablation destroys tissue and denudes any residual nervous and synovial membrane overlying the joint, removing the end point sensory tissue of the joint.

The DenerveX System consists of the DenerveX Kit which contains the DenerveX Device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet FDA cleared.

About Medovex
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company’s first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION
Medovex Corp.
Jason Assad
470-505-9905
Email Contact

Thursday, August 17th, 2017 Uncategorized Comments Off

$YERR Announces Listing on The Nasdaq Global Select Market

NEW YORK, NY and WUHAN, CHINA–(Aug 17, 2017) – Yangtze River Development Limited, (NASDAQ: YERR) (the “Company”), an infrastructure company that engages in the business of real estate development with a port logistic project located in the middle reaches of the Yangtze River, today announced that its common stock has been approved for listing on The Nasdaq Global Select Market and will commence trading on August 18, 2017 under the current ticker symbol “YERR”. The Company’s common stock will continue to trade on the Nasdaq Capital Market until the market close on August 17, 2017.

“Uplisting to The Nasdaq Global Select Market represents an important milestone for Yangtze River Development Limited,” said Xiangyao Liu, CEO, Yangtze River Development Limited. “We believe that trading on The Nasdaq Global Select Market will increase our visibility and enhance our corporate profile. The Nasdaq Global Select Market has the highest initial listing standards of any of the world’s stock markets and we are pleased to be a member of the most elite companies traded globally.”

ABOUT YANGTZE RIVER DEVELOPMENT LTD.:

Yangtze River Development Limited primarily engages in the business of real estate development with a port logistic project located in the middle reaches of the Yangtze River. Wuhan Newport is a large infrastructure development project implemented under China’s latest “One Belt One Road” initiative and is strategically positioned in the “Free Trade Zone” of the Wuhan Port, a crucial trading window between China, the Middle East and Europe. To be fully developed upon completion of three phases, within the logistics center, there will be six operating zones, including port operation area, warehouse and distribution area, cold chain logistics area, rail cargo loading area, exhibition area and residential community. The logistics center is also expected to provide a number of shipping berths for cargo ships of various sizes. Wuhan Newport is expected to provide domestic and foreign businesses a direct access to the Free Trade Zone in Wuhan. The project will include commercial buildings, professional logistic supply chain centers, direct access to the Yangtze River, Wuhan-Xinjiang-Europe Railway and ground transportation, storage and processing centers, IT supporting services, among others.

For additional information please go to: http://www.yerr.com.cn

FORWARD-LOOKING STATEMENTS:

This document includes “forward-looking” statements, as that term is defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. Forward-looking statements are any statements other than statements of historical fact, including statements regarding Company’s expectations, beliefs, hopes, intentions or strategies regarding the future. Among other things, these forward-looking statements may include statements regarding the change of Company’s plan of operation, future opportunities as a result of the matter referenced in the above statements; and any other statements regarding Company’s future beliefs, expectations, plans, intentions, financial condition or performance. In some cases, forward-looking statements can be identified by the use of words such as “may,” “will,” “expects,” “should,” “believes,” “plans,” “anticipates,” “estimates,” “predicts,” “potential,” “continue,” or other words of similar meaning. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those discussed in, or implied by, the forward-looking statements. Factors that might cause such a difference include, but are not limited to, general economic conditions, our financial and business prospects, our capital requirements, our financing prospects, our relationships with employees, and our ability to realize the anticipated benefits of such transaction, and those disclosed as risks in other reports filed by us with the Securities and Exchange Commission, including those described in our most recently filed Annual Report on Form 10-K and subsequent amendment on Form 10-K/A, current report on Form 8-K, and other filings with the SEC.

We caution readers that any such statements are based on currently available operational, financial and competitive information, and they should not place undue reliance on these forward-looking statements, which reflect management’s opinion only as of the date on which they were made. Except as required by law, we disclaim any obligation to review or update these forward-looking statements to reflect events or circumstances as they occur.

CONTACT:
James Coleman
Executive Director
jcoleman@yerr.com.cn
646-861-3315

Thursday, August 17th, 2017 Uncategorized Comments Off

$DRIO Raises $4.28 Million Through Private Placement Offerings

CAESAREA, Israel, August 17, 2017 — DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has signed securities purchase agreements with domestic and non-U.S. investors for the sale of shares of the Company’s common stock and shares of the Company’s newly designated Series B Convertible Preferred Stock in concurrent private placement offerings. The Company expects to conduct a closing with respect to the offerings on or before August 22, 2017. Current shareholders have executed securities purchase agreements accounting for 54% of the securities to be sold in the offerings.

As a part of these private placement transactions, which totals $4.28 million in the aggregate before expenses and placement agent fees, the Company will issue 483,333 shares of common stock at a price per share of $1.80 and 1,894,446 shares of Series B Convertible Preferred Stock at a price per share of $1.80. The Series B Preferred Stock is convertible into shares of the Company’s common stock at a 1:1 ratio and provides for a 6% dividend payable upon the conversion of the preferred shares. The holders of the Series B Preferred Stock will not be entitled to convert such preferred stock into shares of the Company’s common stock until the Company obtains stockholder approval for such issuance. The Company has agreed to file a registration statement covering the resale of the shares of common stock sold in the offering, the shares of common stock underlying the Series B Convertible Preferred Stock and the shares of common stock issuable upon the payment of the dividend, within 60 days of closing.

The private placement was managed by the Company with the assistance of Aegis Capital Corp., which acted as the placement agent for a portion of the offerings.

The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, forward-looking statements are used in this press release when the Company discusses the proposed timing of the closing of the offerings. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate and Media Contact:
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-914-775-5548

DarioHealth Investor Relations Contact:
Hayden IR
Stephen Hart
DRIO@HaydenIR.com
+1-917-658-7878

Thursday, August 17th, 2017 Uncategorized Comments Off

$NTEC Announces Pricing of $50.0 Million Public Offering of Ordinary Shares

JERUSALEM, August 16, 2017 –

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share. The gross proceeds of the offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

The offering is expected to close on or about August 21, 2017, subject to customary closing conditions. Intec Pharma has granted the underwriters a 30-day option to purchase up to approximately 1.6 million additional ordinary shares to cover over-allotments.

Oppenheimer & Co. Inc. is acting as the sole book-running manager, Roth Capital Partners is acting as lead manager, and Maxim Group is acting as co-manager in the offering.

If the over-allotment option is exercised in full, gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $57.5 million.

Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company’s leading product candidate for the indication of treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, for working capital and for general corporate purposes.

The ordinary shares described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on June 19, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov.

Before buying any ordinary shares of Intec Pharma in the offering, you should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that you should consider when making your investment decision. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these ordinary shares may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York, 10004, or by telephone, at 212-667-8563, or e-mail at EquityProspectus@opco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters, and include statements regarding the proposed public offering and the intended use of proceeds from the offering. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, and include the following: the company’s ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; including uncertainty regarding the Company’s ability to enroll the required number of patients therein; whether the Company will be able to complete the offering of ordinary shares, market conditions, and the Company’s ability to fulfill required closing conditions; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company’s drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com

Anne Marie Fields
Senior Vice President
LHA Investor Relations
+1-212-838-3777
afields@lhai.com

Wednesday, August 16th, 2017 Uncategorized Comments Off

$XPLR Appoints Robert McFarland to Its Board of Directors

AUSTIN, Texas, Aug. 16, 2017 — Xplore Technologies Corp. (NASDAQ:XPLR) today announced that it has appointed Robert N. McFarland as a director of the Company. McFarland will fill the vacancy left by the previously announced resignation of Brian E. Usher-Jones, who agreed to continue to serve on the Board of Directors until his replacement was identified and duly appointed or elected to the Board of Directors. McFarland qualifies as an independent director, as defined under The NASDAQ Stock Market Rules.

Phil Sassower, Chairman of Xplore, said: “Bob brings extensive executive management experience with domestic and international enterprises, as well as years of experience with federal government IT services. We look forward to his insights as an independent director as we work to grow revenue in both current and prospective market opportunities. We also wish to thank Brian Usher-Jones for many years of dedicated service as a member of Xplore’s board. Brian has been a key part of our development over the years, and we wish him well.”

Most recently, McFarland served as Assistant Secretary for Information and Technology in the Department of Veterans Affairs (VA) from January 2004 through his retirement in 2006. In this role, he served as Chief Information Officer, advising the Secretary of Veterans Affairs on all matters pertaining to acquisition and management of IT systems. He was also responsible for overseeing operation of the VA’s computer systems and telecommunication networks for medical information, veterans’ benefits payments, life insurance programs and financial management systems.

Prior to his tenure at the VA, McFarland served as vice president of governmental relations for Dell Computer Corporation. He joined Dell in 1996 as vice president and general manager of the federal business segment. He held several senior executive positions at Dell, including managing the company’s global segment, large corporate accounts and government sector. Under his leadership, Dell became the number one supplier of computer systems to the federal government. In 1998 McFarland was named to the “Federal 100” – a joint government and industry award designating the top 100 executives in the federal marketplace.

McFarland’s information technology career also includes executive experience with additional domestic and international enterprises, including senior vice president for the Cerplex Group, Inc., of Southern California, a provider of outsourcing for electronics repair and distribution, and vice president of the Asia Pacific and Middle East regions of AST Research, Inc.

About Xplore Technologies
Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors.   The company’s award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail.  Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on Twitter, FacebookLinkedIn, and YouTube.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

Contact Information:
Tom Wilkinson, Chief Financial Officer
Phone: (512) 637-1162
Email: twilkinson@xploretech.com

Matt Kreps, Darrow Associates Investor Relations
Phone: (512) 696-6401
Email: xplr@darrowir.com
Wednesday, August 16th, 2017 Uncategorized Comments Off

$IDXG Announces Coverage of Thyroid Test by Oxford Health Plans

One of the Northeast’s Largest Health Plans Adds Coverage for ThyraMIR®

PARSIPPANY, N.J., Aug. 16, 2017 — Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that Oxford Health Plans will cover Interpace’s ThyraMIR® test for indeterminate thyroid nodules effective August 1, 2017.   Oxford Health Plans, a UnitedHealthcare company, offers health care benefits to employers and individuals primarily in New York, New Jersey, and Connecticut making it one of the largest health plans in the heavily populated tri-state Region.  Oxford’s commercial insured products and services include traditional health maintenance organizations, preferred and exclusive provider organizations, point-of-service plans and consumer-driven health plans.  In addition, Oxford also offers Medicare plans and third-party administration of employer-funded benefits plans.

With the addition of Oxford’s members, ThyraMIR is now covered for over 250 million lives nationwide, including through Medicare, National, and Regional health plans. This follows the Company’s recent announcement of its National contract with Aetna for its ThyGenX® and ThyraMIR products along with the approval by Cigna of ThyGenX.

The ThyGenX® – ThyraMIR® combination represents the only test in the market that includes the rule-in properties of next-generation sequencing of a patient’s DNA and RNA along with the rule-out capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. Based on current performance, approximately 90% of the Company’s ThyGenX cases are reflexed to ThyraMir for additional assessment.  The Company first launched ThyraMIR on April 15, 2015 making it available to Endocrinologists and Pathologists throughout the country.  Since then, the Company has conducted over 15,000 ThyraMIR tests for nearly 400 physicians and hospitals nationwide.

According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades. Most physicians have traditionally recommended thyroid surgery where thyroid nodule biopsy results are indeterminate, not clearly benign or malignant, following traditional cytopathology review; however, 70%-80% of these surgical outcomes are ultimately benign.  Molecular testing using ThyGenX – ThyraMIR has been shown to reduce the rate of unnecessary surgeries in indeterminate cases.

Jack E. Stover, President and CEO of Interpace Diagnostics stated, “Oxford’s determination to cover ThyraMIR follows a steady stream of payers that have recognized the value that both of our Thyroid products play in identifying the appropriate patients for surgery.” “We are pleased that Oxford has joined the growing list of health plans that cover ThyraMIR and their  members in New York, New Jersey, and Connecticut will now have access to its benefits.”

About Thyroid Nodules, ThyGenX and ThyraMIR Testing

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.  The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier.  MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs.  ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

About Interpace Diagnostics Group, Inc.

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, our ability to restructure our liabilities and other obligations, the market’s acceptance of our molecular diagnostic tests; our ability to retain or secure reimbursement, our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and our ability to maintain our NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 31, 2017 and the amendment on Form 10-K/A filed on April 28, 2017, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the SEC on May 12, 2017, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the SEC on August 10, 2017. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace Diagnostics
Investor Relations:
Paul Kuntz – RedChip
paul@redchip.com
Wednesday, August 16th, 2017 Uncategorized Comments Off

$DGLT Spike Leads to $NDAQ Info Request Halt

NEW YORK, Aug. 16, 2017 — The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in Digiliti Money Group, Inc. (Nasdaq:DGLT) at 11:53:40 Eastern Time for “additional information requested” from the company at a last sale price of $1.0464.

Trading will remain halted until Digiliti Money Group, Inc. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

NDAQO

Nasdaq Media Contact:
Emily Pan
emily.pan@nasdaq.com
Wednesday, August 16th, 2017 Uncategorized Comments Off

$XPLR & DCT Solutions Partner for Organic Agricultural Sector

Android Rugged Tablets Provide New Paperless Auditing, Records System

AUSTIN, Texas, Aug. 15, 2017 — Xplore Technologies Corp. (NASDAQ:XPLR) today announced that Vital Farms, the largest producer of pasture-raised eggs in the U.S. is now using its Android-powered XSLATE D10 rugged tablet platform to manage the more than 130 independent farms under its banner, enforce produce quality standards and maintain its USDA organic certifications. The D10s were delivered to Vital Farms earlier this year by Xplore partner DCT Mobile Solutions as part of its signature Scout Mobility suite, and has since enabled the organic farming cooperative to transfer critical business management systems into electronic form. Specifically, the Xplore rugged tablets are being used by Vital Farms’ inspectors to verify that its agricultural producers are maintaining the 104 different compliancy points required of organic-labeled operations.

“Though farmers still spend a lot of time in the field performing manual labor tasks, they benefit greatly from technology that reduces their manual labor requirements related to business processes that can be automated, such as routine inspections and record-keeping,” commented Mark Holleran, president and CEO of Xplore. “That is why Vital Farms is seeing such a significant payoff for their investment in the Xplore rugged tablet-based solution. They now have a centralized system through which their employees and suppliers can capture, aggregate and share data in real time, which brings more efficiency to all parties’ operations.”

Since the Xplore XSLATE D10 rugged tablet is dust-proof, water resistant and readable in direct sunlight, it is easy for Vital Farms’ auditors to schedule site visits, create and complete inspection checklists, and maintain up-to-date, easily accessible records about each of its independent growers while in the field. Plus, the XLATE D10 is extremely temperature tolerant. It can operate in extreme heat of Central Texas or the winters of the Midwest, which is important given that this organic cooperative is responsible for monitoring farms that span from Kansas, Oklahoma, Missouri and Illinois in the Midwest to Texas, Arkansas, Kentucky, Tennessee and Georgia in the South.

“Anyone in the organic agriculture business will tell you that it’s very expensive and exhausting to conduct audits of geographically disparate farming operations, and maintain compliance with the USDA’s strict regulations, using manual data management systems,” commented Jeff Hinds, vice president of food safety, quality, R&D, grower support, Vital Farms. “We knew that we would eventually gain more control over our collective farming operations, and our costs, once we moved to an electronic records system. However, the return on our investment for the Xplore rugged tablets, and really the total mobility solution, was near immediate. We couldn’t be happier with the value we’re receiving.”

The rugged tablet-based system is not only saving Vital Farms time and money in the management of its extensive paperwork requirements, but it is saving their growers the expense of uncertainty about how to resolve any issues that could hinder their organic certification status. For example, Vital Farms inspectors use the XSLATE D10’s built-in camera to capture pictures of their growers’ infractions, which helps both parties to more effectively recommend the best corrective actions.

“Not only can we identify and address our farmers’ infractions in real-time, but we actually have a better paper trail now than we did when we were using actual paper,” added Hinds.

As Holleran added: “It doesn’t matter your industry classification, every business that operates outside of a traditional four-walled, desk-based office environment needs real-time data management capabilities that only rugged mobile computers can provide.”

To learn more about Xplore’s Android-powered rugged tablet solutions, please visit www.xploretech.com/D10. To read the full Vital Farms case study: http://xploretech.com/vitalfarms

About Xplore Technologies
Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors. The company’s award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail. Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on TwitterFacebookLinkedIn, and YouTube.

Forward-Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

Vital Farms Contact Information:

Jeff Hinds
VP Food Safety, Quality Assurance, Compliance at Vital Farms
Jeff.hinds@vitalfarms.com
877-455-3063

DCT Mobile Solutions Contact Information:

Lacy Moore
Sales Support & Marketing 
lmoore@dctkc.com
816.222.3884

Xplore Contact Information:

Debbie Russo
Director, Marketing 
outboundmarketing@xploretech.com
Tuesday, August 15th, 2017 Uncategorized Comments Off

$FBIO Appointment of Joseph Vazzano to VP of Finance

NEW YORK, Aug. 15, 2017  — Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced the appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer). Mr. Vazzano will assume the responsibilities previously held by Avenue’s Interim Chief Financial Officer, David Horin.

Lucy Lu, M.D., Avenue’s President and Chief Executive Officer, said, “We are delighted to welcome Joe to the Avenue team. He brings extensive financial and accounting expertise to the company, and I look forward to working with him to drive growth for our shareholders. In addition, I would like to thank David for his valuable contributions to Avenue, most notably the strategic guidance that enabled us to achieve a successful initial public offering in June.”

Mr. Vazzano joins Avenue from Intercept Pharmaceuticals, Inc., where he served as Assistant Corporate Controller and oversaw the expansion of the company’s finance and accounting department during its transition from development-stage to a fully integrated commercial organization. Prior to Intercept, Mr. Vazzano served as Assistant Controller at Pernix Therapeutics, where he successfully built an accounting and finance team after a corporate restructuring. Earlier in his career, Mr. Vazzano held roles of increasing responsibility in finance and accounting at NPS Pharmaceuticals, a publicly traded biotechnology company acquired by Shire Pharmaceuticals, and was a senior auditor at KPMG, LLP. Mr. Vazzano holds a B.S. in accounting from Lehigh University in Bethlehem, PA, and is a certified public accountant in New Jersey.

Mr. Vazzano stated, “I am excited to join Avenue at this dynamic time in the company’s development. I look forward to working with Avenue’s strong management team to advance the Phase 3 development and potential commercialization of its postoperative pain therapy IV tramadol in a financially efficient and successful manner.”

About Avenue Therapeutics
Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech Company, is a specialty pharmaceutical company focused on the development and commercialization of an intravenous formulation of tramadol HCl (“IV tramadol”) for the management of postoperative pain. Avenue is headquartered in New York City. For more information, visit www.avenuetx.com.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts: 
Jaclyn Jaffe, Investor Relations
Avenue Therapeutics, Inc.
(781) 652‐4500 
ir@avenuetx.com

Media Relations
Sarah Hall
Phase IV Communications
(215) 313-5638
sarah@phaseivcommunications.com
Tuesday, August 15th, 2017 Uncategorized Comments Off